IQVIA's Institute for Human Data Science's Study found a record number of new drugs launched in the United States in 2018. A third of the new drugs identified as innovative therapies with novel mechanisms of action different from existing therapies. Additionally, the study found that the likelihood that a drug entering clinical development would be a success was 11 percent, down three percent the previous year. Eight trends were also identified as possibilities to increase R&D productivity by double digits over next five years.
Read more of the study here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.